{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:29:40Z","timestamp":1787574580152,"version":"build-2736575974"},"reference-count":243,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41568-026-00951-x","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:26:53Z","timestamp":1783009613000},"page":"689-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia"],"prefix":"10.1038","volume":"26","author":[{"given":"Ilaria","family":"Iacobucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1871-1850","authenticated-orcid":false,"given":"Charles G.","family":"Mullighan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"951_CR1","unstructured":"Cancer Facts & Figures 2026 (American Cancer Society, 2026)."},{"key":"951_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","volume":"2","author":"S Jeha","year":"2021","unstructured":"Jeha, S. et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2, 326\u2013337 (2021).","journal-title":"Blood Cancer Discov."},{"key":"951_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00864-5","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian, H., Pui, C. H. & Jabbour, E. Acute lymphocytic leukaemia. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(25)00864-5 (2025).","journal-title":"Lancet"},{"key":"951_CR4","doi-asserted-by":"publisher","unstructured":"Inaba, H. & Pui, C. H. Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10091926 (2021).","DOI":"10.3390\/jcm10091926"},{"key":"951_CR5","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","volume":"38","author":"SR Rheingold","year":"2024","unstructured":"Rheingold, S. R. et al. Determinants of survival after first relapse of acute lymphoblastic leukemia: a children\u2019s oncology group study. Leukemia 38, 2382\u20132394 (2024).","journal-title":"Leukemia"},{"key":"951_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/ajh.27708","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian, H. & Jabbour, E. Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. Am. J. Hematol. 100, 1205\u20131231 (2025).","journal-title":"Am. J. Hematol."},{"key":"951_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20134","author":"AC Wilke","year":"2025","unstructured":"Wilke, A. C. & Gokbuget, N. The role of blinatumomab in adult acute B lymphoblastic leukaemia. Br. J. Haematol. https:\/\/doi.org\/10.1111\/bjh.20134 (2025).","journal-title":"Br. J. Haematol."},{"key":"951_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35872","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian, H. et al. The evolving therapeutic revolution in adult acute lymphoblastic leukemia. Cancer 131, e35872 (2025).","journal-title":"Cancer"},{"key":"951_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/cells14050371","volume":"14","author":"O Sucre","year":"2025","unstructured":"Sucre, O., Pamulapati, S., Muzammil, Z. & Bitran, J. Advances in therapy of adult patients with acute lymphoblastic leukemia. Cells 14, 371 (2025).","journal-title":"Cells"},{"key":"951_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa, R. et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N. Engl. J. Med. 383, 1613\u20131623 (2020).","journal-title":"N. Engl. J. Med."},{"key":"951_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow, M. R. et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N. Engl. J. Med. 391, 320\u2013333 (2024).","journal-title":"N. Engl. J. Med."},{"key":"951_CR12","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/jcm10173792","volume":"10","author":"I Iacobucci","year":"2021","unstructured":"Iacobucci, I., Kimura, S. & Mullighan, C. G. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J. Clin. Med. 10, 3792 (2021).","journal-title":"J. Clin. Med."},{"key":"951_CR13","first-page":"2275","volume":"141","author":"OK Weinberg","year":"2023","unstructured":"Weinberg, O. K. et al. The international consensus classification of acute leukemias of ambiguous lineage. Blood 141, 2275\u20132277 (2023).","journal-title":"Blood"},{"key":"951_CR14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"951_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"951_CR16","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P Polonen","year":"2024","unstructured":"Polonen, P. et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature 632, 1082\u20131091 (2024).","journal-title":"Nature"},{"key":"951_CR17","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood.2023022920","volume":"145","author":"P Polonen","year":"2025","unstructured":"Polonen, P., Mullighan, C. G. & Teachey, D. T. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood 145, 1464\u20131474 (2025).","journal-title":"Blood"},{"key":"951_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/ng.3301","volume":"47","author":"K Paulsson","year":"2015","unstructured":"Paulsson, K. et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat. Genet. 47, 672\u2013676 (2015).","journal-title":"Nat. Genet."},{"key":"951_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady, S. W. et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat. Genet. 54, 1376\u20131389 (2022).","journal-title":"Nat. Genet."},{"key":"951_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/gcc.20671","volume":"48","author":"K Paulsson","year":"2009","unstructured":"Paulsson, K. & Johansson, B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosom. Cancer 48, 637\u2013660 (2009).","journal-title":"Genes Chromosom. Cancer"},{"key":"951_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood.2024024936","volume":"145","author":"K Purvis","year":"2025","unstructured":"Purvis, K. et al. Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV\/XVI studies. Blood 145, 190\u2013201 (2025).","journal-title":"Blood"},{"key":"951_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s43018-025-00987-2","volume":"6","author":"I Iacobucci","year":"2025","unstructured":"Iacobucci, I. et al. Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features. Nat. Cancer 6, 1242\u20131262 (2025).","journal-title":"Nat. Cancer"},{"key":"951_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70085","volume":"9","author":"M Aertgeerts","year":"2025","unstructured":"Aertgeerts, M. et al. Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment. Hemasphere 9, e70085 (2025).","journal-title":"Hemasphere"},{"key":"951_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu, Z. et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat. Genet. 51, 296\u2013307 (2019).","journal-title":"Nat. Genet."},{"key":"951_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1365-2141.2004.04948.x","volume":"125","author":"CJ Harrison","year":"2004","unstructured":"Harrison, C. J. et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br. J. Haematol. 125, 552\u2013559 (2004).","journal-title":"Br. J. Haematol."},{"key":"951_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cancergen.2019.07.009","volume":"238","author":"AJ Carroll","year":"2019","unstructured":"Carroll, A. J. et al. Masked hypodiploidy: hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: a report from the children\u2019s oncology group. Cancer Genet. 238, 62\u201368 (2019).","journal-title":"Cancer Genet."},{"key":"951_CR27","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1182\/blood-2016-10-743765","volume":"129","author":"S Safavi","year":"2017","unstructured":"Safavi, S. & Paulsson, K. Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 129, 420\u2013423 (2017).","journal-title":"Blood"},{"key":"951_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/ng.2532","volume":"45","author":"L Holmfeldt","year":"2013","unstructured":"Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242\u2013252 (2013).","journal-title":"Nat. Genet."},{"key":"951_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2643-3230.BCD-22-0154","volume":"4","author":"R Kim","year":"2023","unstructured":"Kim, R. et al. Adult low-hypodiploid acute lymphoblastic leukemia emerges from preleukemic TP53-mutant clonal hematopoiesis. Blood Cancer Discov. 4, 134\u2013149 (2023).","journal-title":"Blood Cancer Discov."},{"key":"951_CR30","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood.2020010144","volume":"138","author":"E Paietta","year":"2021","unstructured":"Paietta, E. et al. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood 138, 948\u2013958 (2021).","journal-title":"Blood"},{"key":"951_CR31","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/cncr.11841","volume":"98","author":"SC Raimondi","year":"2003","unstructured":"Raimondi, S. C. et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98, 2715\u20132722 (2003).","journal-title":"Cancer"},{"key":"951_CR32","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1182\/blood-2015-09-671131","volume":"126","author":"CG Mullighan","year":"2015","unstructured":"Mullighan, C. G. et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 126, 2896\u20132899 (2015).","journal-title":"Blood"},{"key":"951_CR33","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","volume":"79","author":"E Diaz-Flores","year":"2019","unstructured":"Diaz-Flores, E. et al. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 79, 2339\u20132351 (2019).","journal-title":"Cancer Res."},{"key":"951_CR34","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2022.281443","volume":"108","author":"H Pariury","year":"2023","unstructured":"Pariury, H. et al. Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia. Haematologica 108, 1272\u20131283 (2023).","journal-title":"Haematologica"},{"key":"951_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","volume":"9","author":"MR Luskin","year":"2025","unstructured":"Luskin, M. R. et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 9, 617\u2013626 (2025).","journal-title":"Blood Adv."},{"key":"951_CR36","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat, V. A. et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 11, 1440\u20131453 (2021).","journal-title":"Cancer Discov."},{"key":"951_CR37","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","volume":"4","author":"DM Moujalled","year":"2020","unstructured":"Moujalled, D. M. et al. Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Adv. 4, 2762\u20132767 (2020).","journal-title":"Blood Adv."},{"key":"951_CR38","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/leu.2013.317","volume":"28","author":"CJ Harrison","year":"2014","unstructured":"Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015\u20131021 (2014).","journal-title":"Leukemia"},{"key":"951_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nature13115","volume":"508","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508, 98\u2013102 (2014).","journal-title":"Nature"},{"key":"951_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/blood.2022019094","volume":"142","author":"Q Gao","year":"2023","unstructured":"Gao, Q. et al. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Blood 142, 711\u2013723 (2023).","journal-title":"Blood"},{"key":"951_CR41","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/blood-2006-08-040436","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman, A. V. et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109, 2327\u20132330 (2007).","journal-title":"Blood"},{"key":"951_CR42","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1200\/JCO.2008.16.1117","volume":"26","author":"A Attarbaschi","year":"2008","unstructured":"Attarbaschi, A. et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J. Clin. Oncol. 26, 3046\u20133050 (2008).","journal-title":"J. Clin. Oncol."},{"key":"951_CR43","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.1073\/pnas.112218799","volume":"99","author":"H Mori","year":"2002","unstructured":"Mori, H. et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl Acad. Sci. USA 99, 8242\u20138247 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"951_CR44","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ng.2874","volume":"46","author":"E Papaemmanuil","year":"2014","unstructured":"Papaemmanuil, E. et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. Genet. 46, 116\u2013125 (2014).","journal-title":"Nat. Genet."},{"key":"951_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/0008-5472.BCD-19-0041","volume":"1","author":"E Waanders","year":"2020","unstructured":"Waanders, E. et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. Blood Cancer Discov. 1, 96\u2013111 (2020).","journal-title":"Blood Cancer Discov."},{"key":"951_CR46","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.23.02238","volume":"42","author":"TC Chang","year":"2024","unstructured":"Chang, T. C. et al. Genomic determinants of outcome in acute lymphoblastic leukemia. J. Clin. Oncol. 42, 3491\u20133503 (2024).","journal-title":"J. Clin. Oncol."},{"key":"951_CR47","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-025-02683-7","volume":"39","author":"L Oksa","year":"2025","unstructured":"Oksa, L. et al. Genomic determinants of therapy response in ETV6::RUNX1 leukemia. Leukemia 39, 2125\u20132139 (2025).","journal-title":"Leukemia"},{"key":"951_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56229-7","volume":"16","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia. Nat. Commun. 16, 1153 (2025).","journal-title":"Nat. Commun."},{"key":"951_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11790","volume":"7","author":"H Lilljebjorn","year":"2016","unstructured":"Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat. Commun. 7, 11790 (2016).","journal-title":"Nat. Commun."},{"key":"951_CR50","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ccell.2015.02.003","volume":"27","author":"H Geng","year":"2015","unstructured":"Geng, H. et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27, 409\u2013425 (2015).","journal-title":"Cancer Cell"},{"key":"951_CR51","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer, U. et al. Genomics and drug profiling of fatal TCF3\u2212HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47, 1020\u20131029 (2015).","journal-title":"Nat. Genet."},{"key":"951_CR52","first-page":"1373","volume":"110","author":"A Zeckanovic","year":"2025","unstructured":"Zeckanovic, A. et al. Update on long-term outcomes of a cohort of patients with TCF3::HLF-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation. Haematologica 110, 1373\u20131378 (2025).","journal-title":"Haematologica"},{"key":"951_CR53","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat. Genet. 48, 569\u2013574 (2016).","journal-title":"Nat. Genet."},{"key":"951_CR54","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3109\/10428194.2012.753450","volume":"54","author":"S Grammatico","year":"2013","unstructured":"Grammatico, S. et al. Lineage switch from pro-B acute lymphoid leukemia to acute myeloid leukemia in a case with t(12;17)(p13;q11)\/TAF15-ZNF384 rearrangement. Leuk. Lymphoma 54, 1802\u20131805 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"951_CR55","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/ng.3691","volume":"48","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481\u20131489 (2016).","journal-title":"Nat. Genet."},{"key":"951_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","volume":"1","author":"EJ Yeoh","year":"2002","unstructured":"Yeoh, E. J. et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133\u2013143 (2002).","journal-title":"Cancer Cell"},{"key":"951_CR57","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470\u2013480 (2009).","journal-title":"N. Engl. J. Med."},{"key":"951_CR58","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/s41375-025-02633-3","volume":"39","author":"RW Wang\u2019ondu","year":"2025","unstructured":"Wang\u2019ondu, R. W. et al. Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 39, 1595\u20131606 (2025).","journal-title":"Leukemia"},{"key":"951_CR59","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","volume":"27","author":"G Martinelli","year":"2009","unstructured":"Martinelli, G. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 27, 5202\u20135207 (2009).","journal-title":"J. Clin. Oncol."},{"key":"951_CR60","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41375-022-01799-4","volume":"37","author":"C Schwab","year":"2023","unstructured":"Schwab, C. et al. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia 37, 529\u2013538 (2023).","journal-title":"Leukemia"},{"key":"951_CR61","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3324\/haematol.2020.250423","volume":"106","author":"M Novakova","year":"2021","unstructured":"Novakova, M. et al. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica 106, 2066\u20132075 (2021).","journal-title":"Haematologica"},{"key":"951_CR62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander, T. B. et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562, 373\u2013379 (2018).","journal-title":"Nature"},{"key":"951_CR63","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1038\/s41375-021-01199-0","volume":"35","author":"S Hirabayashi","year":"2021","unstructured":"Hirabayashi, S. et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia 35, 3272\u20133277 (2021).","journal-title":"Leukemia"},{"key":"951_CR64","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1158\/2643-3230.BCD-21-0163","volume":"3","author":"KM Dickerson","year":"2022","unstructured":"Dickerson, K. M. et al. ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia. Blood Cancer Discov. 3, 240\u2013263 (2022).","journal-title":"Blood Cancer Discov."},{"key":"951_CR65","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/10428194.2022.2148217","volume":"64","author":"S Chiaretti","year":"2023","unstructured":"Chiaretti, S. et al. ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings. Leuk. Lymphoma 64, 483\u2013486 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"951_CR66","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/bloodadvances.2021005318","volume":"5","author":"M Zaliova","year":"2021","unstructured":"Zaliova, M. et al. A novel class of ZNF384 aberrations in acute leukemia. Blood Adv. 5, 4393\u20134397 (2021).","journal-title":"Blood Adv."},{"key":"951_CR67","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","volume":"8","author":"YF Liu","year":"2016","unstructured":"Liu, Y. F. et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 8, 173\u2013183 (2016).","journal-title":"EBioMedicine"},{"key":"951_CR68","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.2016.66.5547","volume":"34","author":"K Suzuki","year":"2016","unstructured":"Suzuki, K. et al. MEF2D\u2013BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J. Clin. Oncol. 34, 3451\u20133459 (2016).","journal-title":"J. Clin. Oncol."},{"key":"951_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13331","volume":"7","author":"Z Gu","year":"2016","unstructured":"Gu, Z. et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat. Commun. 7, 13331 (2016).","journal-title":"Nat. Commun."},{"key":"951_CR70","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ni1454","volume":"8","author":"C Cobaleda","year":"2007","unstructured":"Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian of B cell identity and function. Nat. Immunol. 8, 463\u2013470 (2007).","journal-title":"Nat. Immunol."},{"key":"951_CR71","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature05690","volume":"446","author":"CG Mullighan","year":"2007","unstructured":"Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758\u2013764 (2007).","journal-title":"Nature"},{"key":"951_CR72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1182\/blood-2018-10-882142","volume":"133","author":"M Passet","year":"2019","unstructured":"Passet, M. et al. PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood 133, 280\u2013284 (2019).","journal-title":"Blood"},{"key":"951_CR73","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1038\/s41375-019-0430-z","volume":"33","author":"L Bastian","year":"2019","unstructured":"Bastian, L. et al. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia 33, 1895\u20131909 (2019).","journal-title":"Leukemia"},{"key":"951_CR74","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3324\/haematol.2014.112193","volume":"100","author":"G Fazio","year":"2015","unstructured":"Fazio, G. et al. Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia. Haematologica 100, e14\u2013e17 (2015).","journal-title":"Haematologica"},{"key":"951_CR75","doi-asserted-by":"publisher","unstructured":"Alvey, E. N. et al. B-cell lymphoblastic leukemia\/lymphoma with mutated IKZF1 N159Y: clinical and genetic features of an emerging entity. Haematologica https:\/\/doi.org\/10.3324\/haematol.2024.286626 (2025).","DOI":"10.3324\/haematol.2024.286626"},{"key":"951_CR76","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"JF Li","year":"2018","unstructured":"Li, J. F. et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc. Natl Acad. Sci. USA 115, E11711\u2013E11720 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"951_CR77","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood-2023-174139","volume":"142","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Genomic landscape of down syndrome-associated acute lymphoblastic leukemia. Blood 142, 172\u2013184 (2023).","journal-title":"Blood"},{"key":"951_CR78","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood.2022015444","volume":"139","author":"S Kimura","year":"2022","unstructured":"Kimura, S. et al. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood 139, 3519\u20133531 (2022).","journal-title":"Blood"},{"key":"951_CR79","doi-asserted-by":"publisher","unstructured":"Yasuda, T. et al. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1\/2 mutations. Blood https:\/\/doi.org\/10.1182\/blood.2021011921 (2021).","DOI":"10.1182\/blood.2021011921"},{"key":"951_CR80","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/s41375-022-01557-6","volume":"36","author":"L Bastian","year":"2022","unstructured":"Bastian, L. et al. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment. Leukemia 36, 1676\u20131680 (2022).","journal-title":"Leukemia"},{"key":"951_CR81","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.2019004684","volume":"136","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood 136, 946\u2013956 (2020).","journal-title":"Blood"},{"key":"951_CR82","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.3390\/ijms25169023","volume":"25","author":"L Guarnera","year":"2024","unstructured":"Guarnera, L., D\u2019Addona, M., Bravo-Perez, C. & Visconte, V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives. Int. J. Mol. Sci. 25, 9023 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"951_CR83","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood.2023021501","volume":"142","author":"R Kim","year":"2023","unstructured":"Kim, R. et al. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. Blood 142, 1806\u20131817 (2023).","journal-title":"Blood"},{"key":"951_CR84","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","volume":"388","author":"IM van der Sluis","year":"2023","unstructured":"van der Sluis, I. M. et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N. Engl. J. Med. 388, 1572\u20131581 (2023).","journal-title":"N. Engl. J. Med."},{"key":"951_CR85","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/bloodadvances.2024012638","volume":"9","author":"C Annesley","year":"2025","unstructured":"Annesley, C. et al. Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL. Blood Adv. 9, 2068\u20132078 (2025).","journal-title":"Blood Adv."},{"key":"951_CR86","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa, G. C. et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J. Clin. Oncol. 43, 75\u201384 (2025).","journal-title":"J. Clin. Oncol."},{"key":"951_CR87","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner, F. et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913\u2013919 (2023).","journal-title":"Nature"},{"key":"951_CR88","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa, G. C. et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920\u2013924 (2023).","journal-title":"Nature"},{"key":"951_CR89","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1038\/s41375-021-01333-y","volume":"35","author":"JM Boer","year":"2021","unstructured":"Boer, J. M. et al. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia 35, 2978\u20132982 (2021).","journal-title":"Leukemia"},{"key":"951_CR90","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.3324\/haematol.2018.206961","volume":"104","author":"FM Hormann","year":"2019","unstructured":"Hormann, F. M. et al. NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2. Haematologica 104, e455\u2013e459 (2019).","journal-title":"Haematologica"},{"key":"951_CR91","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood.2021011921","volume":"139","author":"T Yasuda","year":"2022","unstructured":"Yasuda, T. et al. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1\/2 mutations. Blood 139, 1850\u20131862 (2022).","journal-title":"Blood"},{"key":"951_CR92","doi-asserted-by":"publisher","unstructured":"Horns, J. M. et al. IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma. Blood https:\/\/doi.org\/10.1182\/blood.2025031047 (2026).","DOI":"10.1182\/blood.2025031047"},{"key":"951_CR93","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2021.280557","volume":"108","author":"S Bomken","year":"2023","unstructured":"Bomken, S. et al. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement. Haematologica 108, 717\u2013731 (2023).","journal-title":"Haematologica"},{"key":"951_CR94","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Foa","year":"2024","unstructured":"Foa, R. et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J. Clin. Oncol. 42, 881\u2013885 (2024).","journal-title":"J. Clin. Oncol."},{"key":"951_CR95","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","volume":"36","author":"WB Slayton","year":"2018","unstructured":"Slayton, W. B. et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0622. J. Clin. Oncol. 36, 2306\u20132314 (2018).","journal-title":"J. Clin. Oncol."},{"key":"951_CR96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","volume":"18","author":"NJ Short","year":"2025","unstructured":"Short, N. J. et al. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J. Hematol. Oncol. 18, 55 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"951_CR97","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","volume":"114","author":"I Iacobucci","year":"2009","unstructured":"Iacobucci, I. et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell\u2019Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114, 2159\u20132167 (2009).","journal-title":"Blood"},{"key":"951_CR98","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","volume":"129","author":"L Hovorkova","year":"2017","unstructured":"Hovorkova, L. et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood 129, 2771\u20132781 (2017).","journal-title":"Blood"},{"key":"951_CR99","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000445972","volume":"136","author":"Y Kamoda","year":"2016","unstructured":"Kamoda, Y. et al. Philadelphia chromosome-positive acute lymphoblastic leukemia is separated into two subgroups associated with survival by BCR-ABL fluorescence in situ hybridization of segmented cell nuclei: report from a single institution. Acta Haematol. 136, 157\u2013166 (2016).","journal-title":"Acta Haematol."},{"key":"951_CR100","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1080\/10428194.2020.1795160","volume":"61","author":"Z Chen","year":"2020","unstructured":"Chen, Z. et al. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. Leuk. Lymphoma 61, 2831\u20132838 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"951_CR101","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","volume":"55","author":"JC Kim","year":"2023","unstructured":"Kim, J. C. et al. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia. Nat. Genet. 55, 1186\u20131197 (2023).","journal-title":"Nat. Genet."},{"key":"951_CR102","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2023021752","volume":"143","author":"L Bastian","year":"2024","unstructured":"Bastian, L. et al. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL. Blood 143, 1391\u20131398 (2024).","journal-title":"Blood"},{"key":"951_CR103","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.24.00108","volume":"42","author":"R Kim","year":"2024","unstructured":"Kim, R. et al. Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: a GRAAPH-2014 study. J. Clin. Oncol. 42, 3140\u20133150 (2024).","journal-title":"J. Clin. Oncol."},{"key":"951_CR104","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","volume":"130","author":"I Nagel","year":"2017","unstructured":"Nagel, I. et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130, 2027\u20132031 (2017).","journal-title":"Blood"},{"key":"951_CR105","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/ajh.26949","volume":"98","author":"NJ Short","year":"2023","unstructured":"Short, N. J. et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1. Am. J. Hematol. 98, 1196\u20131203 (2023).","journal-title":"Am. J. Hematol."},{"key":"951_CR106","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"G Cazzaniga","year":"2018","unstructured":"Cazzaniga, G. et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin\/T-cell receptor and BCR\/ABL1 methodologies. Haematologica 103, 107\u2013115 (2018).","journal-title":"Haematologica"},{"key":"951_CR107","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005\u20131015 (2014).","journal-title":"N. Engl. J. Med."},{"key":"951_CR108","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","volume":"35","author":"KG Roberts","year":"2017","unstructured":"Roberts, K. G. et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J. Clin. Oncol. 35, 394\u2013401 (2017).","journal-title":"J. Clin. Oncol."},{"key":"951_CR109","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125\u2013134 (2009).","journal-title":"Lancet Oncol."},{"key":"951_CR110","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1182\/blood-2018-05-849554","volume":"132","author":"KG Roberts","year":"2018","unstructured":"Roberts, K. G. et al. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood 132, 861\u2013865 (2018).","journal-title":"Blood"},{"key":"951_CR111","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/bloodadvances.2019000769","volume":"4","author":"V Nardi","year":"2020","unstructured":"Nardi, V. et al. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 4, 106\u2013111 (2020).","journal-title":"Blood Adv."},{"key":"951_CR112","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood.2023023153","volume":"145","author":"TH Tran","year":"2025","unstructured":"Tran, T. H. & Tasian, S. K. How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults. Blood 145, 20\u201334 (2025).","journal-title":"Blood"},{"key":"951_CR113","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood.2019001244","volume":"134","author":"I Tanasi","year":"2019","unstructured":"Tanasi, I. et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood 134, 1351\u20131355 (2019).","journal-title":"Blood"},{"key":"951_CR114","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1182\/blood.2023023120","volume":"143","author":"I van Outersterp","year":"2024","unstructured":"van Outersterp, I. et al. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain. Blood 143, 2178\u20132189 (2024).","journal-title":"Blood"},{"key":"951_CR115","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood 137, 471\u2013484 (2021).","journal-title":"Blood"},{"key":"951_CR116","first-page":"1105","volume":"110","author":"I Aldoss","year":"2025","unstructured":"Aldoss, I. et al. Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica 110, 1105\u20131114 (2025).","journal-title":"Haematologica"},{"key":"951_CR117","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1182\/blood.2024026482","volume":"145","author":"YY Ding","year":"2025","unstructured":"Ding, Y. Y. et al. Targeting senescent stemlike subpopulations in Philadelphia chromosome-like acute lymphoblastic leukemia. Blood 145, 1195\u20131210 (2025).","journal-title":"Blood"},{"key":"951_CR118","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clml.2024.08.005","volume":"25","author":"I Iacobucci","year":"2025","unstructured":"Iacobucci, I. & Papayannidis, C. Approach to BCR::ABL1-like acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 25, 13\u201322 (2025).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"951_CR119","first-page":"1783","volume":"9","author":"MC Bene","year":"1995","unstructured":"Bene, M. C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9, 1783\u20131786 (1995).","journal-title":"Leukemia"},{"key":"951_CR120","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith, E. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10, 147\u2013156 (2009).","journal-title":"Lancet Oncol."},{"key":"951_CR121","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood.2023021906","volume":"143","author":"D O\u2019Connor","year":"2024","unstructured":"O\u2019Connor, D. et al. Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. Blood 143, 933\u2013937 (2024).","journal-title":"Blood"},{"key":"951_CR122","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood.2024024300","volume":"144","author":"S Rahman","year":"2024","unstructured":"Rahman, S. et al. Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia. Blood 144, 2319\u20132326 (2024).","journal-title":"Blood"},{"key":"951_CR123","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1182\/blood-2011-10-388504","volume":"119","author":"JE Haydu","year":"2012","unstructured":"Haydu, J. E. et al. An activating intragenic deletion in NOTCH1 in human T-ALL. Blood 119, 5211\u20135214 (2012).","journal-title":"Blood"},{"key":"951_CR124","doi-asserted-by":"publisher","first-page":"18261","DOI":"10.1073\/pnas.0606108103","volume":"103","author":"T Palomero","year":"2006","unstructured":"Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl Acad. Sci. USA 103, 18261\u201318266 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"951_CR125","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/leu.2010.237","volume":"24","author":"A Ferrando","year":"2010","unstructured":"Ferrando, A. NOTCH mutations as prognostic markers in T-ALL. Leukemia 24, 2003\u20132004 (2010).","journal-title":"Leukemia"},{"key":"951_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-15233-2","volume":"25","author":"H Al Kuwari","year":"2025","unstructured":"Al Kuwari, H. et al. NOTCH1 mutation status as a prognostic biomarker in T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis. BMC Cancer 25, 1820 (2025).","journal-title":"BMC Cancer"},{"key":"951_CR127","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"951_CR128","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","volume":"11","author":"LE Montefiori","year":"2021","unstructured":"Montefiori, L. E. et al. Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia. Cancer Discov. 11, 2846\u20132867 (2021).","journal-title":"Cancer Discov."},{"key":"951_CR129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood-2021-150841","volume":"138","author":"D Di Giacomo","year":"2021","unstructured":"Di Giacomo, D. et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. Blood 138, 773\u2013784 (2021).","journal-title":"Blood"},{"key":"951_CR130","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031402","author":"D Di Giacomo","year":"2026","unstructured":"Di Giacomo, D. et al. Deregulation of FOXF1\/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia. Blood https:\/\/doi.org\/10.1182\/blood.2025031402 (2026).","journal-title":"Blood"},{"key":"951_CR131","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031466","author":"K Mimura","year":"2026","unstructured":"Mimura, K. et al. BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL. Blood https:\/\/doi.org\/10.1182\/blood.2025031466 (2026).","journal-title":"Blood"},{"key":"951_CR132","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ajh.26758","volume":"98","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. Am. J. Hematol. 98, 66\u201378 (2023).","journal-title":"Am. J. Hematol."},{"key":"951_CR133","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/blood.2025028985","volume":"146","author":"LE Montefiori","year":"2025","unstructured":"Montefiori, L. E. et al. Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia. Blood 146, 2350\u20132356 (2025).","journal-title":"Blood"},{"key":"951_CR134","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1182\/blood.2021015036","volume":"140","author":"R Tirtakusuma","year":"2022","unstructured":"Tirtakusuma, R. et al. Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia. Blood 140, 1875\u20131890 (2022).","journal-title":"Blood"},{"key":"951_CR135","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s43018-022-00370-5","volume":"3","author":"S Hetzel","year":"2022","unstructured":"Hetzel, S. et al. Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nat. Cancer 3, 768\u2013782 (2022).","journal-title":"Nat. Cancer"},{"key":"951_CR136","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/sj.leu.2404257","volume":"20","author":"J Roman-Gomez","year":"2006","unstructured":"Roman-Gomez, J. et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 20, 1445\u20131448 (2006).","journal-title":"Leukemia"},{"key":"951_CR137","doi-asserted-by":"publisher","first-page":"e65373","DOI":"10.1371\/journal.pone.0065373","volume":"8","author":"M Borssen","year":"2013","unstructured":"Borssen, M. et al. Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS ONE 8, e65373 (2013).","journal-title":"PLoS ONE"},{"key":"951_CR138","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cam4.1917","volume":"8","author":"Z Haider","year":"2019","unstructured":"Haider, Z. et al. An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression. Cancer Med. 8, 311\u2013324 (2019).","journal-title":"Cancer Med."},{"key":"951_CR139","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/pbc.25958","volume":"63","author":"M Borssen","year":"2016","unstructured":"Borssen, M. et al. DNA methylation adds prognostic value to minimal residual disease status in pediatric T-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 63, 1185\u20131192 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"951_CR140","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41375-019-0626-2","volume":"34","author":"S Kimura","year":"2020","unstructured":"Kimura, S. et al. DNA methylation-based classification reveals difference between pediatric T-cell acute lymphoblastic leukemia and normal thymocytes. Leukemia 34, 1163\u20131168 (2020).","journal-title":"Leukemia"},{"key":"951_CR141","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2643-3230.BCD-20-0059","volume":"1","author":"J Roels","year":"2020","unstructured":"Roels, J. et al. Aging of preleukemic thymocytes drives CpG island hypermethylation in T-cell acute lymphoblastic leukemia. Blood Cancer Discov. 1, 274\u2013289 (2020).","journal-title":"Blood Cancer Discov."},{"key":"951_CR142","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1182\/blood-2024-208641","volume":"144","author":"A Liapodimitri","year":"2024","unstructured":"Liapodimitri, A. et al. Mapping the dynamic DNA methylation landscape in pre-B ALL from diagnosis to relapse reveals a role for aberrant PRC2 regulation. Blood 144, 4127\u20134127 (2024).","journal-title":"Blood"},{"key":"951_CR143","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1182\/blood-2009-06-227660","volume":"114","author":"DJ Stumpel","year":"2009","unstructured":"Stumpel, D. J. et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 114, 5490\u20135498 (2009).","journal-title":"Blood"},{"key":"951_CR144","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41588-025-02321-z","volume":"57","author":"TL Steinicke","year":"2025","unstructured":"Steinicke, T. L. et al. Rapid epigenomic classification of acute leukemia. Nat. Genet. 57, 2456\u20132467 (2025).","journal-title":"Nat. Genet."},{"key":"951_CR145","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/leu.2017.89","volume":"31","author":"AC Kramer","year":"2017","unstructured":"Kramer, A. C. et al. Dnmt3a regulates T-cell development and suppresses T-ALL transformation. Leukemia 31, 2479\u20132490 (2017).","journal-title":"Leukemia"},{"key":"951_CR146","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3324\/haematol.2018.197848","volume":"104","author":"J Bond","year":"2019","unstructured":"Bond, J. et al. DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. Haematologica 104, 1617\u20131625 (2019).","journal-title":"Haematologica"},{"key":"951_CR147","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ejh.12964","volume":"99","author":"B Szarzynska-Zawadzka","year":"2017","unstructured":"Szarzynska-Zawadzka, B. et al. Cost-effective screening of DNMT3A coding sequence identifies somatic mutation in pediatric T-cell acute lymphoblastic leukemia. Eur. J. Haematol. 99, 514\u2013519 (2017).","journal-title":"Eur. J. Haematol."},{"key":"951_CR148","doi-asserted-by":"publisher","first-page":"e2110758118","DOI":"10.1073\/pnas.2110758118","volume":"118","author":"M Bensberg","year":"2021","unstructured":"Bensberg, M. et al. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 118, e2110758118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"951_CR149","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13072-019-0278-5","volume":"12","author":"CJ Poole","year":"2019","unstructured":"Poole, C. J., Lodh, A., Choi, J. H. & van Riggelen, J. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Epigenetics Chromatin 12, 41 (2019).","journal-title":"Epigenetics Chromatin"},{"key":"951_CR150","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-021-01068-4","volume":"14","author":"M Simonin","year":"2021","unstructured":"Simonin, M. et al. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. J. Hematol. Oncol. 14, 74 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"951_CR151","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235\u2013239 (2011).","journal-title":"Nature"},{"key":"951_CR152","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1158\/2159-8290.CD-20-1771","volume":"12","author":"J Li","year":"2022","unstructured":"Li, J. et al. PRC2 inhibitors overcome glucocorticoid resistance driven by NSD2 mutation in pediatric acute lymphoblastic leukemia. Cancer Discov. 12, 186\u2013203 (2022).","journal-title":"Cancer Discov."},{"key":"951_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4469","volume":"5","author":"BG Mar","year":"2014","unstructured":"Mar, B. G. et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 5, 3469 (2014).","journal-title":"Nat. Commun."},{"key":"951_CR154","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2014-05-577270","volume":"125","author":"J Van der Meulen","year":"2015","unstructured":"Van der Meulen, J. et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood 125, 13\u201321 (2015).","journal-title":"Blood"},{"key":"951_CR155","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1101\/gad.276790.115","volume":"30","author":"A Benyoucef","year":"2016","unstructured":"Benyoucef, A. et al. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia. Genes. Dev. 30, 508\u2013521 (2016).","journal-title":"Genes. Dev."},{"key":"951_CR156","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature13605","volume":"514","author":"P Ntziachristos","year":"2014","unstructured":"Ntziachristos, P. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513\u2013517 (2014).","journal-title":"Nature"},{"key":"951_CR157","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41588-020-0602-9","volume":"52","author":"A Kloetgen","year":"2020","unstructured":"Kloetgen, A. et al. Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. Nat. Genet. 52, 388\u2013400 (2020).","journal-title":"Nat. Genet."},{"key":"951_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100442","volume":"3","author":"KR Barnett","year":"2023","unstructured":"Barnett, K. R. et al. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom. 3, 100442 (2023).","journal-title":"Cell Genom."},{"key":"951_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51492-6","volume":"15","author":"S Narang","year":"2024","unstructured":"Narang, S. et al. Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia. Nat. Commun. 15, 7425 (2024).","journal-title":"Nat. Commun."},{"key":"951_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42565-z","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia. Nat. Commun. 14, 6792 (2023).","journal-title":"Nat. Commun."},{"key":"951_CR161","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/363358a0","volume":"363","author":"AM Ford","year":"1993","unstructured":"Ford, A. M. et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363, 358\u2013360 (1993).","journal-title":"Nature"},{"key":"951_CR162","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1073\/pnas.95.8.4584","volume":"95","author":"AM Ford","year":"1998","unstructured":"Ford, A. M. et al. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl Acad. Sci. USA 95, 4584\u20134588 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"951_CR163","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1182\/blood.2019002215","volume":"134","author":"D Hein","year":"2019","unstructured":"Hein, D. et al. The preleukemic TCF3\u2013PBX1 gene fusion can be generated in utero and is present in approximately 0.6% of healthy newborns. Blood 134, 1355\u20131358 (2019).","journal-title":"Blood"},{"key":"951_CR164","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1182\/blood-2011-07-366542","volume":"118","author":"G Cazzaniga","year":"2011","unstructured":"Cazzaniga, G. et al. Developmental origins and impact of BCR\u2013ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood 118, 5559\u20135564 (2011).","journal-title":"Blood"},{"key":"951_CR165","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/blood.V96.1.264","volume":"96","author":"T Yagi","year":"2000","unstructured":"Yagi, T. et al. Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia. Blood 96, 264\u2013268 (2000).","journal-title":"Blood"},{"key":"951_CR166","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-018-0015-6","volume":"18","author":"M Greaves","year":"2018","unstructured":"Greaves, M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat. Rev. Cancer 18, 471\u2013484 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"951_CR167","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1182\/blood-2017-09-808402","volume":"131","author":"D Schafer","year":"2018","unstructured":"Schafer, D. et al. Five percent of healthy newborns have an ETV6\u2013RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood 131, 821\u2013826 (2018).","journal-title":"Blood"},{"key":"951_CR168","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10555-019-09841-1","volume":"39","author":"D Hein","year":"2020","unstructured":"Hein, D., Borkhardt, A. & Fischer, U. Insights into the prenatal origin of childhood acute lymphoblastic leukemia. Cancer Metastasis Rev. 39, 161\u2013171 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"951_CR169","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24\u201337 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"951_CR170","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.bjc.6605982","volume":"104","author":"L Kinlen","year":"2011","unstructured":"Kinlen, L. Childhood leukaemia, nuclear sites, and population mixing. Br. J. Cancer 104, 12\u201318 (2011).","journal-title":"Br. J. Cancer"},{"key":"951_CR171","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. BCR\u2013ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110\u2013114 (2008).","journal-title":"Nature"},{"key":"951_CR172","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ni.3160","volume":"16","author":"S Swaminathan","year":"2015","unstructured":"Swaminathan, S. et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat. Immunol. 16, 766\u2013774 (2015).","journal-title":"Nat. Immunol."},{"key":"951_CR173","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1158\/2159-8290.CD-15-0892","volume":"5","author":"A Martin-Lorenzo","year":"2015","unstructured":"Martin-Lorenzo, A. et al. Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility. Cancer Discov. 5, 1328\u20131343 (2015).","journal-title":"Cancer Discov."},{"key":"951_CR174","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1158\/0008-5472.CAN-17-0701","volume":"77","author":"G Rodriguez-Hernandez","year":"2017","unstructured":"Rodr\u00edguez-Hernandez, G. et al. Infection exposure promotes ETV6\u2013RUNX1 precursor B-cell leukemia via impaired H3K4 demethylases. Cancer Res. 77, 4365\u20134377 (2017).","journal-title":"Cancer Res."},{"key":"951_CR175","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/leu.2016.152","volume":"30","author":"M Fidanza","year":"2016","unstructured":"Fidanza, M. et al. Inhibition of precursor B-cell malignancy progression by Toll-like receptor ligand-induced immune responses. Leukemia 30, 2116\u20132119 (2016).","journal-title":"Leukemia"},{"key":"951_CR176","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1182\/blood-2014-12-580001","volume":"125","author":"T Moriyama","year":"2015","unstructured":"Moriyama, T., Relling, M. V. & Yang, J. J. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 125, 3988\u20133995 (2015).","journal-title":"Blood"},{"key":"951_CR177","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/ng.2754","volume":"45","author":"S Shah","year":"2013","unstructured":"Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226\u20131231 (2013).","journal-title":"Nat. Genet."},{"key":"951_CR178","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2018.03.021","volume":"33","author":"ML Churchman","year":"2018","unstructured":"Churchman, M. L. et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell 33, 937\u2013948 e938 (2018).","journal-title":"Cancer Cell"},{"key":"951_CR179","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/bloodadvances.2018030635","volume":"3","author":"E Rampersaud","year":"2019","unstructured":"Rampersaud, E. et al. Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Adv. 3, 1039\u20131046 (2019).","journal-title":"Blood Adv."},{"key":"951_CR180","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1200\/JCO.2011.38.0345","volume":"30","author":"H Xu","year":"2012","unstructured":"Xu, H. et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 30, 751\u2013757 (2012).","journal-title":"J. Clin. Oncol."},{"key":"951_CR181","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/ng.2803","volume":"45","author":"V Perez-Andreu","year":"2013","unstructured":"Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45, 1494\u20131498 (2013).","journal-title":"Nat. Genet."},{"key":"951_CR182","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jama.293.12.1485","volume":"293","author":"M Stanulla","year":"2005","unstructured":"Stanulla, M. et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293, 1485\u20131489 (2005).","journal-title":"JAMA"},{"key":"951_CR183","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2005-08-3379","volume":"107","author":"MV Relling","year":"2006","unstructured":"Relling, M. V., Pui, C. H., Cheng, C. & Evans, W. E. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107, 843\u2013844 (2006).","journal-title":"Blood"},{"key":"951_CR184","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"SK Yang","year":"2014","unstructured":"Yang, S. K. et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat. Genet. 46, 1017\u20131020 (2014).","journal-title":"Nat. Genet."},{"key":"951_CR185","doi-asserted-by":"publisher","first-page":"55809","DOI":"10.1074\/jbc.M411767200","volume":"279","author":"MT Abrams","year":"2004","unstructured":"Abrams, M. T., Robertson, N. M., Yoon, K. & Wickstrom, E. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J. Biol. Chem. 279, 55809\u201355817 (2004).","journal-title":"J. Biol. Chem."},{"key":"951_CR186","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1097\/HS9.0000000000000939","volume":"7","author":"T Beder","year":"2023","unstructured":"Beder, T. et al. The gene expression classifier ALLCatchR identifies B-cell precursor all subtypes and underlying developmental trajectories across age. Hemasphere 7, e939 (2023).","journal-title":"Hemasphere"},{"key":"951_CR187","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s43018-024-00863-5","volume":"6","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia. Nat. Cancer 6, 102\u2013122 (2025).","journal-title":"Nat. Cancer"},{"key":"951_CR188","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61222-1","volume":"16","author":"J Costea","year":"2025","unstructured":"Costea, J. et al. Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia. Nat. Commun. 16, 5413 (2025).","journal-title":"Nat. Commun."},{"key":"951_CR189","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377\u20131380 (2008).","journal-title":"Science"},{"key":"951_CR190","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature25186","volume":"553","author":"G Tzoneva","year":"2018","unstructured":"Tzoneva, G. et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553, 511\u2013514 (2018).","journal-title":"Nature"},{"key":"951_CR191","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3324\/haematol.2017.176362","volume":"103","author":"NA Evensen","year":"2018","unstructured":"Evensen, N. A. et al. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica 103, 830\u2013839 (2018).","journal-title":"Haematologica"},{"key":"951_CR192","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/2643-3230.BCD-20-0216","volume":"3","author":"RJ Vanner","year":"2022","unstructured":"Vanner, R. J. et al. Multiomic profiling of central nervous system leukemia identifies mRNA translation as a therapeutic target. Blood Cancer Discov. 3, 16\u201331 (2022).","journal-title":"Blood Cancer Discov."},{"key":"951_CR193","doi-asserted-by":"publisher","first-page":"E439","DOI":"10.1002\/ajh.26713","volume":"97","author":"BJ Lee","year":"2022","unstructured":"Lee, B. J. et al. CD19-directed immunotherapy use in KMT2A-rearranged acute leukemia: a case report and literature review of increased lymphoid to myeloid lineage switch. Am. J. Hematol. 97, E439\u2013E443 (2022).","journal-title":"Am. J. Hematol."},{"key":"951_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.89","volume":"7","author":"CL Haddox","year":"2017","unstructured":"Haddox, C. L. et al. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A\/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J. 7, e607 (2017).","journal-title":"Blood Cancer J."},{"key":"951_CR195","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.23266","volume":"87","author":"JG Rossi","year":"2012","unstructured":"Rossi, J. G. et al. Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am. J. Hematol. 87, 890\u2013897 (2012).","journal-title":"Am. J. Hematol."},{"key":"951_CR196","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504\u20131506 (2018).","journal-title":"Nat. Med."},{"key":"951_CR197","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282\u20131295 (2015).","journal-title":"Cancer Discov."},{"key":"951_CR198","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","volume":"34","author":"M Asnani","year":"2020","unstructured":"Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia 34, 1202\u20131207 (2020).","journal-title":"Leukemia"},{"key":"951_CR199","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig, F. et al. Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129, 100\u2013104 (2017).","journal-title":"Blood"},{"key":"951_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-021-07435-2","volume":"22","author":"Y Huo","year":"2021","unstructured":"Huo, Y. et al. Blinatumomab-induced T cell activation at single cell transcriptome resolution. BMC Genomics 22, 145 (2021).","journal-title":"BMC Genomics"},{"key":"951_CR201","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella, M. & Maus, M. V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 14, 357\u2013362 (2016).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"951_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583044","volume":"16","author":"L Cao","year":"2025","unstructured":"Cao, L., Leclercq-Cohen, G., Klein, C., Sorrentino, A. & Bacac, M. Mechanistic insights into resistance mechanisms to T cell engagers. Front. Immunol. 16, 1583044 (2025).","journal-title":"Front. Immunol."},{"key":"951_CR203","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell, J. et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31, 2181\u20132190 (2017).","journal-title":"Leukemia"},{"key":"951_CR204","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1158\/2643-3230.BCD-21-0087","volume":"3","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies. Blood Cancer Discov. 3, 103\u2013115 (2022).","journal-title":"Blood Cancer Discov."},{"key":"951_CR205","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2024023930","volume":"144","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood 144, 61\u201373 (2024).","journal-title":"Blood"},{"key":"951_CR206","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood.2024026085","volume":"145","author":"CS Escherich","year":"2025","unstructured":"Escherich, C. S. et al. DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood 145, 1182\u20131194 (2025).","journal-title":"Blood"},{"key":"951_CR207","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2024028215","volume":"146","author":"CS Escherich","year":"2025","unstructured":"Escherich, C. S. et al. Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin. Blood 146, 471\u2013481 (2025).","journal-title":"Blood"},{"key":"951_CR208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58868-2","volume":"16","author":"P Domizi","year":"2025","unstructured":"Domizi, P. et al. IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies. Nat. Commun. 16, 3800 (2025).","journal-title":"Nat. Commun."},{"key":"951_CR209","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N Gokbuget","year":"2024","unstructured":"Gokbuget, N. et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood 143, 1891\u20131902 (2024).","journal-title":"Blood"},{"key":"951_CR210","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/bloodadvances.2024015441","volume":"9","author":"NJ Short","year":"2025","unstructured":"Short, N. J. et al. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 9, 1442\u20131451 (2025).","journal-title":"Blood Adv."},{"key":"951_CR211","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","volume":"36","author":"M Stanulla","year":"2018","unstructured":"Stanulla, M. et al. IKZF1(plus) defines a new minimal residual Disease-Dependent Very-Poor prognostic profile in pediatric B-Cell precursor acute lymphoblastic leukemia. J. Clin. Oncol. 36, 1240\u20131249 (2018).","journal-title":"J. Clin. Oncol."},{"key":"951_CR212","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2025-31","volume":"146","author":"X Zhong","year":"2025","unstructured":"Zhong, X. et al. Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial. Blood 146, 31 (2025).","journal-title":"Blood"},{"key":"951_CR213","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.2023023754","volume":"144","author":"M Simonin","year":"2024","unstructured":"Simonin, M. et al. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. Blood 144, 1570\u20131580 (2024).","journal-title":"Blood"},{"key":"951_CR214","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.beha.2017.07.002","volume":"30","author":"X Chen","year":"2017","unstructured":"Chen, X. & Wood, B. L. How do we measure MRD in ALL and how should measurements affect decisions. Re: treatment and prognosis? Best Pract. Res. Clin. Haematol. 30, 237\u2013248 (2017).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"951_CR215","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen, P. et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129, 347\u2013357 (2017).","journal-title":"Blood"},{"key":"951_CR216","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJ van Dongen","year":"1999","unstructured":"van Dongen, J. J. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901\u20131928 (1999).","journal-title":"Leukemia"},{"key":"951_CR217","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","volume":"33","author":"H Pfeifer","year":"2019","unstructured":"Pfeifer, H. et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia 33, 1910\u20131922 (2019).","journal-title":"Leukemia"},{"key":"951_CR218","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41375-024-02272-0","volume":"38","author":"VHJ van der Velden","year":"2024","unstructured":"van der Velden, V. H. J. et al. Analysis of measurable residual disease by IG\/TR gene rearrangements: quality assurance and updated EuroMRD guidelines. Leukemia 38, 1315\u20131322 (2024).","journal-title":"Leukemia"},{"key":"951_CR219","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Bruggemann","year":"2010","unstructured":"Bruggemann, M. et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24, 521\u2013535 (2010).","journal-title":"Leukemia"},{"key":"951_CR220","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1182\/blood.2024027175","volume":"146","author":"M Kotrova","year":"2025","unstructured":"Kotrova, M. et al. NGS-based IG\/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation. Blood 146, 585\u2013589 (2025).","journal-title":"Blood"},{"key":"951_CR221","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham, M. et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120, 5173\u20135180 (2012).","journal-title":"Blood"},{"key":"951_CR222","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","volume":"6","author":"NJ Short","year":"2022","unstructured":"Short, N. J. et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 6, 4006\u20134014 (2022).","journal-title":"Blood Adv."},{"key":"951_CR223","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood.2022017003","volume":"141","author":"M Svaton","year":"2023","unstructured":"Svaton, M. et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood 141, 529\u2013533 (2023).","journal-title":"Blood"},{"key":"951_CR224","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","volume":"131","author":"B Wood","year":"2018","unstructured":"Wood, B. et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 131, 1350\u20131359 (2018).","journal-title":"Blood"},{"key":"951_CR225","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/JCO.2017.74.0449","volume":"36","author":"D O\u2019Connor","year":"2018","unstructured":"O\u2019Connor, D. et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J. Clin. Oncol. 36, 34\u201343 (2018).","journal-title":"J. Clin. Oncol."},{"key":"951_CR226","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/leu.2016.234","volume":"31","author":"CH Pui","year":"2017","unstructured":"Pui, C. H. et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia 31, 333\u2013339 (2017).","journal-title":"Leukemia"},{"key":"951_CR227","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41375-024-02209-7","volume":"38","author":"T Burmeister","year":"2024","unstructured":"Burmeister, T. et al. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia. Leukemia 38, 1600\u20131603 (2024).","journal-title":"Leukemia"},{"key":"951_CR228","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/sj.leu.2402636","volume":"16","author":"VH van der Velden","year":"2002","unstructured":"van der Velden, V. H. et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 16, 1432\u20131436 (2002).","journal-title":"Leukemia"},{"key":"951_CR229","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","volume":"5","author":"L Muffly","year":"2021","unstructured":"Muffly, L. et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 5, 3147\u20133151 (2021).","journal-title":"Blood Adv."},{"key":"951_CR230","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2025029096","volume":"146","author":"I Iacobucci","year":"2025","unstructured":"Iacobucci, I. Age shapes the immunogenetic fingerprint of ALL. Blood 146, 525\u2013526 (2025).","journal-title":"Blood"},{"key":"951_CR231","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2020.03.012","volume":"37","author":"E Kilgour","year":"2020","unstructured":"Kilgour, E., Rothwell, D. G., Brady, G. & Dive, C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37, 485\u2013495 (2020).","journal-title":"Cancer Cell"},{"key":"951_CR232","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.pathol.2021.01.004","volume":"53","author":"JK Lim","year":"2021","unstructured":"Lim, J. K., Kuss, B. & Talaulikar, D. Role of cell-free DNA in haematological malignancies. Pathology 53, 416\u2013426 (2021).","journal-title":"Pathology"},{"key":"951_CR233","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41375-024-02461-x","volume":"39","author":"S Lei","year":"2025","unstructured":"Lei, S. et al. Genomic profiling of circulating tumor DNA for childhood cancers. Leukemia 39, 420\u2013430 (2025).","journal-title":"Leukemia"},{"key":"951_CR234","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.958673","volume":"12","author":"S Sampathi","year":"2022","unstructured":"Sampathi, S. et al. Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Front. Oncol. 12, 958673 (2022).","journal-title":"Front. Oncol."},{"key":"951_CR235","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1200\/OP-24-00648","volume":"20","author":"JG Schroers-Martin","year":"2024","unstructured":"Schroers-Martin, J. G. & Alizadeh, A. A. Cell-free DNA in hematologic malignancies. JCO Oncol. Pract. 20, 1491\u20131499 (2024).","journal-title":"JCO Oncol. Pract."},{"key":"951_CR236","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41587-022-01551-4","volume":"41","author":"H Jeong","year":"2023","unstructured":"Jeong, H. et al. Functional analysis of structural variants in single cells using Strand-seq. Nat. Biotechnol. 41, 832\u2013844 (2023).","journal-title":"Nat. Biotechnol."},{"key":"951_CR237","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1182\/bloodadvances.2021005894","volume":"6","author":"B Schmidt","year":"2022","unstructured":"Schmidt, B. et al. ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia. Blood Adv. 6, 4093\u20134097 (2022).","journal-title":"Blood Adv."},{"key":"951_CR238","first-page":"1741","volume":"109","author":"Z Hu","year":"2024","unstructured":"Hu, Z. et al. MD-ALL: an integrative platform for molecular diagnosis of B-acute lymphoblastic leukemia. Haematologica 109, 1741\u20131754 (2024).","journal-title":"Haematologica"},{"key":"951_CR239","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00479-5","volume":"7","author":"O Krali","year":"2023","unstructured":"Krali, O. et al. Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia. NPJ Precis. Oncol. 7, 131 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"951_CR240","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.87","volume":"7","author":"S Laukkanen","year":"2017","unstructured":"Laukkanen, S. et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer J. 7, e604 (2017).","journal-title":"Blood Cancer J."},{"key":"951_CR241","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho, Y. et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat. Cancer 2, 284\u2013299 (2021).","journal-title":"Nat. Cancer"},{"key":"951_CR242","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fped.2017.00258","volume":"5","author":"H Inaba","year":"2017","unstructured":"Inaba, H., Azzato, E. M. & Mullighan, C. G. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable lesions: the St. Jude Children\u2019s Research Hospital approach. Front. Pediatr. 5, 258 (2017).","journal-title":"Front. Pediatr."},{"key":"951_CR243","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1182\/blood.2022015853","volume":"140","author":"EJ Duncavage","year":"2022","unstructured":"Duncavage, E. J. et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood 140, 2228\u20132247 (2022).","journal-title":"Blood"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00951-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00951-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:07:51Z","timestamp":1787573271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41568-026-00951-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":243,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["951"],"URL":"https:\/\/doi.org\/10.1038\/s41568-026-00951-x","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"22 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.I. reported consultation honoraria from Arima and travel expenses reimbursed by Mission Bio and Takara for invited talks. C.G.M. received research funding from AbbVie and Pfizer, honoraria from Amgen and Illumina, and royalty payments from Cyrus, and\u00a0is on an advisory board for Illumina.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}